Job losses?

Quote












Not till after the holidays. Definitely by March-- probably Jan/Feb timeframe. Expect a major cut-- bigger than last time. You should be looking for a new job NOW if you feel you could be in jeopardy!!! Good luck!
 






Management here - nothing is going to happen this year & who knows about next year. There are many variables which will dictate how things pan out. Layoffs will almost always occur toward the end of a year because budgets are done on a calendar year worldwide. The US is only a portion of a company that employs 116,000 people.

Novartis will always need someone to call on their customers. There will probably be fewer in the long run, but we will always need some salespeople. If you choose to ride it out all you can do is to do your job everyday and try not to worry. Of course you should have "plan B", but you can't dwell on whether or not we will have layoffs.
 




































Well looks like you've got your answer. Novartis job cuts all over the business news. To the manager who posted above saying nothing is happening this year or next.....guess you've been sorely mistaken! Or maybe you're just too drunk on the kook-aid....
 












Yo Yiminez has no clear long-term vision and Pharma as we know it is over. Yo's deep-reaching decisions are pointed to the most important customer: Stock holders. Everything is oriented toward buoying the stock price to attract investors while the limited intellect in Executive Management tries (5 years too late) to figure out what to do after Diovan goes off patent. Everything will be licensing and outsourcing, and in time, Novartis- like others- will become essentially a venture capital firm that invests in medicine. There's nothing attractive about this to investors, but that's the way the cooties crumble.
 






10/25/11 Novartis's blockbuster plans to develop a game-changing combo COPD therapy for the U.S. market have run into a serious delay. The pharma giant noted today that investigators will need to come up with a fresh set of clinical data for NVA237--one half of the late-stage QVA149 program, which will now require new clinical studies--derailing its schedule on the much more important combo therapy.

Read more: Novartis signals serious U.S. delay for blockbuster COPD program - FierceBiotech

http://www.fiercebiotech.com/story/...m_medium=nl&utm_source=internal#ixzz1bqBiM2Pw
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech
 






Top Bottom
Back
Quote